Thioredoxin reductase (TrxR) is the first selenoenzyme containing selenocysteine in the active center and FAD as a second prosthetic group. TrxR catalyses the NADPH-dependent reduction of tioredoxin and of many other physiologically important substrates. TrxR exhibits many-fold increased activity in tumor cells and stimulates their proliferation as well the phenotype changes. Some gold compounds and a number of other clinically and experimentally used drugs have been shown to inhibit TrxR. The involvement of TrxR/Trx/NADPH system in broad spectrum of cellular processes renders it potential target for therapeutic approaches.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.